Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ablynx N.V.
A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.
The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Ablynx NV